Clinical Trial Update: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for U3-1402 in patients with metastatic or unresectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• U3-1402 (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING